

### AMENDMENTS TO THE CLAIMS

Claims 1-21 are pending.

Claims 1 and 8-12 are being amended.

After the amendments, claims 1-21 will be pending.

This listing of claims replaces all prior versions and listings of claims in the application:

#### Listing of Claims

1. (Currently amended) A method for delivering a virus to a solid tumor to reduce growth of the tumor, comprising administering an effective amount of virus to a subject bearing the tumor, wherein the virus is capable of selectively killing tumor cells, by a base administration of injecting ~~delivering~~ on the same day a composition comprising the virus into ~~to~~ multiple sites inside the solid tumor, wherein the volume of the composition injected ~~delivered~~ per site is between about 10% to about 100% of the volume of the tumor.
2. (Original) The method of claim 1 wherein the virus is reovirus.
3. (Original) The method of claim 2 wherein the reovirus is a mammalian reovirus.
4. (Original) The method of claim 3 wherein the mammalian reovirus is a human reovirus.
5. (Original) The method of claim 4 wherein the human reovirus is a serotype 3 virus.
6. (Original) The method of claim 5 wherein the serotype 3 virus is a Dearing strain virus.
7. (Original) The method of claim 1 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, p53-expressing viruses, the ONYX-015 virus, the Delta24 virus, vesicular stomatitis virus, the herpes simplex virus 1 mutant which is defective in hrR3, Newcastle disease virus,

encephalitis virus, herpes zoster virus, hepatitis virus, influenza virus, varicella virus, and measles virus.

8. (Currently amended) The method of claim 1 wherein the virus is injected into ~~delivered~~ to at least 3 sites inside the tumor mass.

9. (Currently amended) The method of claim 1 wherein the virus is injected into ~~delivered~~ to at least 5 sites inside the tumor mass.

10. (Currently amended) The method of claim 1 wherein the virus is injected into ~~delivered~~ to one site per about 0.25 cubic centimeter of the tumor.

11. (Currently amended) The method of claim 1 wherein the volume of the composition injected per site is at least 30% of the volume of the tumor.

12. (Currently amended) The method of claim 1 wherein the volume of the composition injected per site is at least 50% of the volume of the tumor.

13. (Previously presented) The method of claim 1 wherein the total volume of the virus composition delivered is between about 10% to about 100% of the volume of the tumor.

14. (Previously presented) The method of claim 1 further comprising at least one additional administration selected from the group consisting of:

- (a) delivering the virus by using a transdermal patch, a spray on the skin, or topical administration, wherein the tumor is a superficial tumor; and
- (b) delivering the virus systemically.

15. (Original) The method of claim 14 wherein the at least one additional administration is conducted before or after the base administration.

16. (Original) The method of claim 14 wherein the at least one additional administration is concurrent with the base administration.
17. (Original) The method of claim 14 wherein the virus is reovirus.
18. (Original) The method of claim 17 wherein the reovirus is a mammalian reovirus.
19. (Original) The method of claim 18 wherein the mammalian reovirus is a human reovirus.
20. (Original) The method of claim 19 wherein the human reovirus is a serotype 3 virus.
21. (Original) The method of claim 20 wherein the serotype 3 virus is a Dearing strain virus.